• Clinical science

Thrombotic thrombocytopenic purpura

Abstract

Thrombotic thrombocytopenic purpura (TTP) is a thrombotic microangiopathy, a condition in which microthrombi, consisting primarily of platelets, form and occlude the microvasculature (i.e. the arterioles and capillaries). The other main thrombotic microangiopathy is hemolytic uremic syndrome (HUS). TTP occurs primarily in adults and is typically due to acquired autoantibodies against a proteolytic enzyme that cleaves von Willebrand factor (vWF). It is a clinical diagnosis based on a pentad of findings: fever, neurological abnormalities, thrombocytopenia, microangiopathic hemolytic anemia, and impaired renal function. If TTP is strongly suspected and initial laboratory tests support the diagnosis, treatment should begin immediately, as the condition may be fatal if left untreated. First-line treatment is plasma exchange therapy.

Epidemiology

  • Primarily adult patients (median age at diagnosis: ∼ 40 years)
  • More common in women and black populations

References:[1][2]

Epidemiological data refers to the US, unless otherwise specified.

Etiology

  • ADAMTS13 deficiency
    • Acquired TTP (∼ 95%): autoantibodies against ADAMTS13, a vWF-cleaving metalloprotease (see “Pathophysiology” below)
    • Congenital TTP (∼ 5%): gene mutations resulting in deficiency of ADAMTS13
  • Risk factors

References:[3][4][5][6]

Pathophysiology

TTP is a thrombotic microangiopathy, a condition in which microthrombi form and occlude the microvasculature; . The other main thrombotic microangiopathy is hemolytic uremic syndrome (HUS). The two conditions have some pathophysiological similarities and share some clinical findings. However, they have distinct etiologies, with TTP being caused by a deficiency of ADAMTS13.

  1. Autoantibodies or gene mutationsdeficiency of ADAMTS13
  2. vWF accumulation on endothelial cell surfaces
  3. Platelet adhesion and microthrombosis
  4. Red blood cells (RBCs) are fragmented by microthrombi blockages, resulting in hemolytic anemia.
  5. Microthrombi block arterioles, capillaries → end-organ ischemia and damage, especially in the brain and kidneys (potentially resulting in acute kidney injury or stroke).

ADAMTS13 deficiency → excess vWF → microthrombus formation → blockage of small vesselsRBC fragmentation (hemolysis) and end-organ damage

References:[7][3][2][4]

Clinical features

TTP patients are typically previously healthy adults. The pentad of clinical findings consists of:

  1. Fever
  2. Neurological signs and symptoms
  3. Low platelet count (i.e. thrombocytopenia)
  4. Microangiopathic hemolytic anemia
  5. Impaired renal function

The typical patient is a previously healthy adult presenting with mental status changes, fever, petechiae, fatigue, and pallor. Laboratory tests will then indicate hemolytic anemia and possibly acute kidney injury (AKI). Impaired kidney function may not be present, and only a minority of patients will present with all five clinical findings.

TTP symptoms: “Nasty Fever Ruined My Tubes” → N – Neurological symptoms, F – Fever, R – Renal function impairment, M – Microangiopathic hemolytic anemia, T – Thrombocytopenia


References:[7][1][8]

Diagnostics

References:[9][1][5]

Differential diagnoses

The differential diagnoses listed here are not exhaustive.

Treatment

Treatment should be started after a presumptive diagnosis is made based on clinical features and initial labs (e.g., blood count, peripheral smear, creatinine).

TTP requires urgent diagnosis and treatment! Waiting for test results to confirm ADAMTS13 deficiency should not delay treatment.
References:[10]

Complications

TTP can result in microthrombus formation and complications in many organs of the body.

References:[9][10][1][11]

We list the most important complications. The selection is not exhaustive.

Prognosis

The prognosis depends primarily on prompt initiation of treatment. Timely treatment can prevent acute complications (AKI, coma, and death), as well as progression to chronic renal failure.

References:[9][10]

Prevention